欧盟 - 芬兰文 - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopic - muut dermatologiset valmisteet - staquis on tarkoitettu lievän tai keskivaikean atooppisen ihottuman aikuisilla ja lapsilla yli 2-vuotiaiden kanssa ≤ 40% kehon pinta-alan (bsa) vaikuttaa.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

eli lilly nederland b.v. - lisproinsuliini - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen hoito aikuisilla, nuorilla ja yli 1-vuotiailla lapsilla. diabetes mellituksen hoito aikuisilla.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

sanofi winthrop industrie - insuliini aspart - diabetes mellitus - diabeetilla käytettävät lääkkeet - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - insuliini aspart - diabetes mellitus - diabeetilla käytettävät lääkkeet - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - tietoinen sedaatio - psyykenlääkkeiden - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - liikalihavuus - antiobesity preparations, excl. ruokavalion tuotteita - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - hemostaatit - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migreenihäiriöt - kipulääkkeet - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolaktoni - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.